Radioactive antibody combo aims to stop prostate cancer spread

NCT ID NCT00859781

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no visible metastases. The main goal is to see how many remain free of detectable spread after 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-J591 (a radioactive antibody) and ketoconazole (a hormone-blocking drug)
What this could lead to: If this works, it could offer a new way to delay or prevent the spread of prostate cancer in high-risk patients whose PSA is rising despite hormone therapy.
What could go wrong: This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The combination therapy can cause side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATE BIOCHEMICALLY RELAPSED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Cedars Sinai

Los Angeles, California, 90048, United States
Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
The University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
USC/Norris Comprehensive cancer center

Los Angeles, California, 90089, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Utah

Salt Lake City, Utah, 84108, United States
Weill Cornell Medical College

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.